^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    MRT-2359

    i
    Other names: MRT-2359, GSPT1-directed MGD
    Company:
    Monte Rosa Therap
    Drug class:
    GSPT1 degrader
    Related drugs:
    26d
    Development of XYD113 as a potent and highly selective GSPT1 degrader for cancer therapy. (PubMed, Acta Pharmacol Sin)
    In vivo, oral administration of XYD113 (5 mg/kg, daily for 21 days) significantly inhibited 22Rv1 xenograft growth (TGI = 46%) and showed a favorable safety profile in BALB/c-nude mice. Together, these findings highlight XYD113 as a promising therapeutic degrader worthy of further development for the treatment of MYC-driven cancers.
    Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • IKZF1 (IKAROS Family Zinc Finger 1) • CRBN (Cereblon) • GSPT1 (G1 To S Phase Transition 1) • SALL4 (Spalt Like Transcription Factor 4)
    |
    MRT-2359
    5ms
    MRT-2359-001: Study of Oral MRT-2359 in Selected Cancer Patients (clinicaltrials.gov)
    P1/2, N=174, Active, not recruiting, Monte Rosa Therapeutics, Inc | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HER-2 (Human epidermal growth factor receptor 2) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • MYCN (MYCN Proto-Oncogene BHLH Transcription Factor)
    |
    HR positive • HER-2 negative • MYCN amplification
    |
    enzalutamide • fulvestrant • MRT-2359
    over2years
    Study of Oral MRT-2359 in Selected Cancer Patients (clinicaltrials.gov)
    P1/2, N=135, Recruiting, Monte Rosa Therapeutics, Inc
    Trial completion date • Trial primary completion date
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • MYCN (MYCN Proto-Oncogene BHLH Transcription Factor)
    |
    MYCN amplification • MYC expression
    |
    MRT-2359
    over3years
    Study of Oral MRT-2359 in Selected Cancer Patients (clinicaltrials.gov)
    P1/2, N=133, Recruiting, Monte Rosa Therapeutics, Inc | Not yet recruiting --> Recruiting
    Enrollment open
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • MYCN (MYCN Proto-Oncogene BHLH Transcription Factor)
    |
    MYCN amplification • MYC expression
    |
    MRT-2359
    almost4years
    Study of Oral MRT-2359 in Selected Cancer Patients (clinicaltrials.gov)
    P1/2, N=133, Not yet recruiting, Monte Rosa Therapeutics, Inc
    New P1/2 trial
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • MYCN (MYCN Proto-Oncogene BHLH Transcription Factor)
    |
    MYCN amplification • MYC expression
    |
    MRT-2359